Akorn receives 'warning letter' from FDA related to a manufacturing facility
Akorn Inc. said Wednesday that it received a warning letter from the Food and Drug Administration, related to an inspection of the generic drug maker's Decatur, Illinois manufacturing facility. The stock was halted for news, and was inactive prior to the halt. The FDA had investigated the facility in April and May 2018. The company said it will respond to the FDA letter, dated Jan. 4, within 15 working days. "Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter," Akorn said in a statement. The stock has tumbled 39% over the past three months, while the S&P 500 has lost 10.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.